These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. Trizepatide, on the other hand, targets all three incretin receptors – GLP-1, GIP, and glucose – leading to a combined effect.